EMA Withdrawn: Temozolomide Sandoz (temozolomide) — Sandoz GmbH

View source ↗

Summary

EMA withdrew Temozolomide Sandoz (temozolomide) from the market; therapeutic area Glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Temozolomide Sandoz (temozolomide)

Snippet

Status: Withdrawn. Therapeutic area: Glioma. MAH: Sandoz GmbH. Decision date: 15/09/2022